Iron Deficiency Anemia

Slides:

Advertisements

Similar presentations

Erythropoietin and hemodialysis (anemia) M 陳嬿雅 104 陳佩儀.

Advertisements

End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.

Anemia in chronic kidney disease

Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.

Zuragen® Lock (an investigational device)

Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.

~ Make a Difference ~ Become a Nephrology Nurse. Incidence (rate of occurrence) –220 per million in 1992 –334 per million in 2000 Prevalence (number of.

NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.

 Stored in the body as ferritin  Deficiency result from negative iron balance due to depletion of stores and/or inadequate intake.  Iron deficiency.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.

Anemia in Hemodialysis 1. 2 Etiology The anemia of chronic kidney disease (CKD) is primarily due to insufficient production of the glycoprotein hormone.

Creative marketing strategies can drive significant financial returns Please turn your audio on.

Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015

Medical Directorate, National Kidney Foundation, Singapore

From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):

Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN

Algorithm for iron therapy in management of anemia of CKD

Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Chapter 2: Clinical Indicators and Preventive Care

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

New and Emerging Management Options for Anemia in CKD

The Nurse View.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Updates Abound in Hyperkalemia Management

CKD Complications By Alaina Darby.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

New options for the anemia of chronic kidney disease

Statin Selection in Special Patient Populations: A Case Challenge

Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.

Addressing Iron Deficiency in Chronic HF

Iron Deficiency Anemia

American Journal of Kidney Diseases

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients.

End-stage renal disease in developing countries

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Obstacles and Advances in Anemia Management in Patients With CKD

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Oral Anticoagulation in AF

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

The risk of hospitalization and modality failure with home dialysis

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Managing CKD-Associated Anemia in Challenging Patients

Meeting the challenges of the new K/DOQI guidelines

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Iron Deficiency in Heart Failure

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

When Good Isn't Good Enough

Assessing the Burden of Hyperkalemia

Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study Eric D.

Resolved: The Case for CKD Clinics

Assessing the Burden of Hyperkalemia

Volume 55, Issue 5, Pages (May 1999)

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

Volume 66, Issue 2, Pages (August 2004)

Anemia Explored.

Lipids, the Heart, and the Kidney

Challenges and Emerging Solutions in Anemia Management Explored

Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary

CKD Is a Global Burden With Major Implications

Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.

Presentation transcript:

Iron Deficiency Anemia

Program Goals

Patient Case Stage 4 CKD (Predialysis)

Other Pertinent Lab Values for Joanna

Causes of Anemia

Clinical Impact of Iron Deficiency Anemia

Iron Replacement Therapy IV vs Oral

Unmet Clinical Need Oral Iron for the Treatment of Iron Deficiency Anemia in CKD

Safety of IV and Oral Iron in CKD

Weighing the Risk vs Benefits of IV Iron

Patient Case Home Hemodialysis

Other Pertinent Lab Values for James

Erythropoietin IV vs Subcutaneous

Role of Ferric Citrate

Efficacy of Ferric Citrate in Patients on Dialysis

Role of Sucroferric Oxyhydroxide

Peritoneal Dialysis (PD) Approach to Treatment

Role of FGF23 in Phosphate Regulation

Abbreviations